Singapore, March 11 -- WuXi XDC Cayman Inc., a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specialising in antibody-drug conjugates (ADCs) and other bioconjugates (XDCs), has announced the signing of a Memorandum of Understanding (MoU) with AbTis, a leading ADC biotechnology startup based inSouth Korea.

This partnership brings together AbTis' proprietary site-selective conjugation platform AbClick and China-based WuXi XDC's integrated discovery services and all-in-one development & manufacturing platform. The collaboration aims to accelerate ADC therapeutic innovation by integrating AbTis' cutting-edge technology into WuXi XDC's toolbox, while fostering new opportunities for global clients.

WuXi...